Persistence of overactive bladder pharmacological treatment in women as reflected from large‐scale real‐world data of prescription claims: A retrospective cohort study

Abstract

Introduction and ObjectivesMedical treatments for overactive bladder (OAB) have proven efficacy in controlled trials. However, 1‐year treatment persistence is reported to be as low as 25% for anticholinergics and 40% for β3 agonists. Real‐world data on treatment continuation and treatment sequence is limited. Therefore, we aimed to study treatment persistence trends in women initiated on OAB medications.Materials and MethodsWe used advanced data‐mining techniques to query the largest regional provider's medication purchase database, dispensing for patients, for all women initiating OAB pharmacotherapy between 2010 and 2020. Treatment persistence was measured as days in which the patient was in possession of medication and nonpersistence was defined as prescription nonrefilling for 90 days. We employed a Sankey diagram to explore trends in OAB medication acquisition and treatment sequence. We compared treatment persistence using Kaplan–Meier survival curves and pairwise log‐rank analysis.ResultsHere, 46 079 women made 791 681 unique claims of OAB medications. Only 39% of the patients tried more than one OAB formulation, including dose change. The overall persistence rate for all drugs was 55% in 30 days, 46% in 90 days, and 37% per year. The persistence rate for Mirabegron at 30 days was 54%, 42% at 90 days, and 17% at 1 year. Overall, persistence rates were unchanged when stratifying by the time Mirabegron insurance acceptance into coverage (p > 0.05).ConclusionsReal‐world OAB pharmacotherapy persistence rates are lower than previously reported. The introduction of Mirabegron did not seem to improve these rates or affect the treatment sequence.